Drug Trial Radar · NCT06085183
Indigotindisulfonate Sodium as an Aid in Determination of Ureteral Patency in Patient's With Renal Impairment
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Dec 20, 2023
Primary completion
Dec 30, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Prove pharmIndustry
- Sponsor type
- Industry
- First posted
- Oct 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, randomized, multicenter study to evaluate the efficacy and safety of two dose levels (2.5 mL and 5.0 mL) of Indigotindisulfonate Sodium Injection, USP 0.8% when used as an aid in the determination of ureteral patency in patients with different degrees of renal impairment.
Conditions
- Ureter Injury
Interventions
Saline Injection 0.9%Other
Placebo
Indigotindisulfonate sodium 0.8%Drug
Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Paired sample difference (Bludigo - Saline) in urine jet conspicuity score.Time frame: 10 to 15 minutes post study drug administration
- Responders to BludigoTime frame: 10 to 15 minutes post study drug administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Albany Medical Center
Albany, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.